ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
Longitudinal Imaging of T Cells and Inflammatory Demyelination in a Preclinical Model of Multiple Sclerosis Using
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 25 citations in OpenAlex.
- Metabolic [¹⁸F]F-AraG PET imaging of T Cell activation: a functional complement to cell-specific immune tracers.EJNMMI research · 2026Review
- Insights and challenges on animal models for progressive multiple sclerosis.Journal of neuroinflammation · 2026Review
- Neurogenesis and Neuroinflammation in Dialogue: Mapping Gaps, Modulating Microglia, Rewiring Aging.Cells · 2026Review
- Translational molecular imaging and drug development in multiple sclerosis.Theranostics · 2026Review
- Cytotoxic T lymphocytes and their dual role in modulating blood-brain barrier integrity in immune-mediated neurological pathologies.Journal of translational medicine · 2025Review
- A Feasibility Study of [Molecular imaging and biology · 2024Article
- The promise and reality of new immune profiling technologies.Nature immunology · 2024Article
- Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection.Science translational medicine · 2024Article
- [Communications biology · 2024Article
- A feasibility study of [18F]F-AraG positron emission tomography (PET) for cardiac imaging - myocardial viability in ischemia-reperfusion injury model.Research square · 2024Article
- Emergence of the brain-border immune niches and their contribution to the development of neurodegenerative diseases.Frontiers in immunology · 2024Review
- The Promise of Molecular Imaging: Focus on Central Nervous System Infections.The Journal of infectious diseases · 2023Review
- Measuring Pathology in Patients with Multiple Sclerosis Using Positron Emission Tomography.Current neurology and neuroscience reports · 2023Review
- Multimodal Molecular Imaging Reveals Tissue-Based T Cell Activation and Viral RNA Persistence for Up to 2 Years Following COVID-19.medRxiv : the preprint server for health sciences · 2023Article
- Fluorinated carbohydrates forChemical Society reviews · 2023Review
- Visual evoked potentials waveform analysis to measure intracortical damage in a preclinical model of multiple sclerosis.Frontiers in cellular neuroscience · 2023Article
- An improved radiosynthesis of [Journal of labelled compounds & radiopharmaceuticals · 2022Article
- Simplified and accessible [Journal of labelled compounds & radiopharmaceuticals · 2022Article
- HIV Compartmentalization in the CNS and Its Impact in Treatment Outcomes and Cure Strategies.Current HIV/AIDS reports · 2022Review
- Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Lymphocytes and innate immune cells are key drivers of multiple sclerosis (MS) and are the main target of MS disease-modifying therapies (DMT). Ex vivo analyses of MS lesions have revealed cellular heterogeneity and variable T cell levels, which may have important implications for patient stratification and choice of DMT. Although MRI has proven valuable to monitor DMT efficacy, its lack of specificity for cellular subtypes highlights the need for complementary methods to improve lesion characterization. Here, we evaluated the potential of 2'-deoxy-2'-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.